Circulating basophils in patients with type IIb autoimmune chronic spontaneous urticaria have a lower histamine content

Katrine Baumann*, Jennifer Astrup Sørensen, Ditte G Zhang, Misbah N Ghazanfar, Per Stahl Skov, Anders Woetmann, Simon Francis Thomsen

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

6 Downloads (Pure)

Abstract

Background: Patients suffering from chronic spontaneous urticaria (CSU) are typically classified as type I or type IIb autoimmune CSU, but further patient stratification is hindered by the lack of biomarkers. Objectives: We investigated whether the histamine content of individual basophils differ between patient subtypes in CSU to evaluate its potential as a biomarker. Methods: A total of 101 patients diagnosed with CSU were included in the study. The histamine content per circulating basophil was derived from the basophil count in peripheral blood and levels of total cellular blood histamine. These measures, together with results from the serum-induced basophil histamine release assay (s-BHRA), were correlated to information on demographics, clinical characteristics, patient reported outcomes and laboratory analyses. Results: The histamine content per basophil was significantly different between s-BHRA negative and -positive patients (0.175 vs. 1.40 pg/cell, p < 0.001) and showed a significant negative correlation to the degree of basophil activation in s-BHRA (ρ = −0.209, p = 0.036). Furthermore, the amount of histamine in individual basophils was found to be significantly correlated with levels of total cellular blood histamine (ρ = 0.376, p < 0.001), eosinophil counts (ρ = 0.205, p = 0.040), levels of thyroid stimulating hormone (ρ = −0.246, p = 0.014) and titre of antibodies against thyroid peroxidase (ρ = −0.216, p = 0.031) and thyroglobulin (ρ = −0.203, p = 0.044). Conclusions: Low content of intracellular histamine in circulating basophils is associated with known markers of type IIb autoimmune CSU. Further studies are required to assess whether the amount of histamine in basophils can be used to monitor or predict response to treatment in patients.

Original languageEnglish
JournalJEADV Clinical Practice
Volume3
Issue number2
Pages (from-to)658-663
ISSN2768-6566
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Keywords

  • basophil histamine release assay
  • basophils
  • biomarkers
  • chronic spontaneous urticaria
  • histamine
  • patient stratification

Cite this